Literature DB >> 29501913

The development of glutamate-based antidepressants is taking longer than expected.

Ricardo Garay1, Carlos A Zarate2, Icilio Cavero3, Yong-Ku Kim4, Thomas Charpeaud5, Phil Skolnick6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29501913      PMCID： PMC6211562          DOI： 10.1016/j.drudis.2018.02.006

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


× No keyword cloud information.
  10 in total

1.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Authors:  Carlos A Zarate; Jaskaran B Singh; Paul J Carlson; Nancy E Brutsche; Rezvan Ameli; David A Luckenbaugh; Dennis S Charney; Husseini K Manji
Journal:  Arch Gen Psychiatry       Date:  2006-08

2.  Antidepressant effects of ketamine in depressed patients.

Authors:  R M Berman; A Cappiello; A Anand; D A Oren; G R Heninger; D S Charney; J H Krystal
Journal:  Biol Psychiatry       Date:  2000-02-15       Impact factor: 13.382

Review 3.  Investigational drugs in recent clinical trials for treatment-resistant depression.

Authors:  Ricardo P Garay; Carlos A Zarate; Thomas Charpeaud; Leslie Citrome; Christoph U Correll; Ahcène Hameg; Pierre-Michel Llorca
Journal:  Expert Rev Neurother       Date:  2017-01-29       Impact factor: 4.618

4.  Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test.

Authors:  Phil Skolnick; Tomasz Kos; Janusz Czekaj; Piotr Popik
Journal:  Acta Neuropsychiatr       Date:  2015-04-10       Impact factor: 3.403

Review 5.  Ketamine: translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders.

Authors:  C A Zarate; R Machado-Vieira
Journal:  Mol Psychiatry       Date:  2017-01-10       Impact factor: 15.992

6.  Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity.

Authors:  J Persson; J Hasselström; A Maurset; I Oye; J O Svensson; O Almqvist; H Scheinin; L L Gustafsson; O Almqvist
Journal:  Eur J Clin Pharmacol       Date:  2002-02       Impact factor: 2.953

Review 7.  Glutamate-based antidepressants: 20 years on.

Authors:  Phil Skolnick; Piotr Popik; Ramon Trullas
Journal:  Trends Pharmacol Sci       Date:  2009-11       Impact factor: 14.819

8.  An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Authors:  Sheldon H Preskorn; Bryan Baker; Sheela Kolluri; Frank S Menniti; Michael Krams; Jaren W Landen
Journal:  J Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.153

9.  R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects.

Authors:  C Yang; Y Shirayama; J-c Zhang; Q Ren; W Yao; M Ma; C Dong; K Hashimoto
Journal:  Transl Psychiatry       Date:  2015-09-01       Impact factor: 6.222

Review 10.  The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant.

Authors:  Joseph R Moskal; Jeffrey S Burgdorf; Patric K Stanton; Roger A Kroes; John F Disterhoft; Ronald M Burch; M Amin Khan
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363
  10 in total
  3 in total

1.  Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model.

Authors:  Kai Zhang; Hidetoh Toki; Yuko Fujita; Min Ma; Lijia Chang; Youge Qu; Shingo Harada; Tetsuhiro Nemoto; Akiko Mizuno-Yasuhira; Jun-Ichi Yamaguchi; Shigeyuki Chaki; Kenji Hashimoto
Journal:  Psychopharmacology (Berl)       Date:  2018-09-13       Impact factor: 4.530

2.  A wake-up call: Sleep physiology and related translational discrepancies in studies of rapid-acting antidepressants.

Authors:  Okko Alitalo; Roosa Saarreharju; Ioline D Henter; Carlos A Zarate; Samuel Kohtala; Tomi Rantamäki
Journal:  Prog Neurobiol       Date:  2021-08-14       Impact factor: 10.885

3.  "This Is Something That Changed My Life": A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders.

Authors:  O Merve Mollaahmetoglu; Johanna Keeler; Katherine J Ashbullby; Eirini Ketzitzidou-Argyri; Meryem Grabski; Celia J A Morgan
Journal:  Front Psychiatry       Date:  2021-08-16       Impact factor: 4.157
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.